3,475 results on '"Kasper, Siegfried"'
Search Results
2. Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
3. Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
4. General Principles of Pharmacologic Therapy
5. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
6. Hypomanic symptoms in major depressive disorder: Prognostic impact and treatment issues
7. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials
8. The clinical perspective on late-onset depression in European real-world treatment settings
9. Effects of bilateral sequential theta-burst stimulation on 5-HT1A receptors in the dorsolateral prefrontal cortex in treatment-resistant depression: a proof-of-concept trial
10. Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach
11. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
12. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
13. Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data
14. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
15. ABCB1 variants and sex affect serotonin transporter occupancy in the brain
16. Reply to: “The serotonin theory of depression: a systematic umbrella review of the evidence” published by Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA in Molecular Psychiatry (2022 Jul 20. doi: 10.1038/s41380-022-01661-0)
17. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder
18. General Principles of Pharmacologic Therapy
19. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns
20. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
21. Initiating Antidepressant Medication: What is the Most Important Factor?
22. Die therapieresistente Depression (TRD) – Herausforderungen und praktisches Management
23. Oxytocin receptor gene methylation as a molecular marker for severity of depressive symptoms in affective disorder patients
24. Identifying the Common Genetic Basis of Antidepressant Response
25. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder
26. Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study
27. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
28. Die Rolle von Phytotherapie bei COVID-19-assoziierter Angst und Depression: Beispiele aus der Praxis.
29. Neuroimaging in Seasons and Winter Depression
30. The Impact of Genetic Polymorphisms on Neuroreceptor Binding: Results from PET and SPECT Neuroreceptor Imaging Studies
31. Urological adverse drug reactions of psychotropic medication in psychiatric inpatients – A drug surveillance report from German-speaking countries
32. Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression
33. The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder : A Meta-Analysis of Randomized Controlled Trials
34. Melancholic features in major depression – a European multicenter study
35. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
36. The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression
37. Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers
38. Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression
39. Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study
40. The clinical perspective on late-onset depression in European real-world treatment settings
41. Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain
42. Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study
43. Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care.
44. Big Data Guided Interventions: Predicting Treatment Response
45. Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples
46. Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm
47. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts
48. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
49. Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials
50. Overcoming the myths of esketamine administration: different and not difficult
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.